Always felt that a drug for vet would undercut and even stigmatise its application for humans. Think about it. Might have been path of least resistance but it was short-sighted, a Haliday idea. Perhaps should have concentrated on human application then gone human to vet. Stelfonta developing a reputation for being challenging in its treatment presentation hasnt helped. And revenue dropping like a stone. Maybe can it as a vet drug, not worth it given the paltry revenue. So much for 100 mill VG projected. Not even 1/100 of that. Time for rebrand. Whatever vet trials they are doing should be pulled or run its course for the data only. That route has so far not proven a to be a good business decision.
- Forums
- ASX - By Stock
- Qbiotics
Always felt that a drug for vet would undercut and even...
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online